Roche's Multiple Sclerosis Injection Gets EU Approval
By Adria Calatayud
Roche Holding said its Ocrevus injection for multiple sclerosis got approval in the European Union.
The Swiss pharmaceutical company said Tuesday that the European Commission granted marketing authorization for a subcutaneous version of its Ocrevus injection, adding to the previously approved intravenous infusion. The approval was based on data from a late-stage trial that showed safety and efficacy for the injection was comparable to the intravenous formulation, the company said.
The subcutaneous injection makes it easier for patients to access their treatments, the company said.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
June 25, 2024 01:27 ET (05:27 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
10 Top-Performing Dividend Stocks of Q3 2024
-
33 Undervalued Stocks
-
Communication Services: Cable’s Broadband Dominance Isn’t as Strong as It Once Was
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities
-
Best- and Worst-Performing Stocks of Q3 2024
-
Top Stocks to Own From the Best Fund Managers
-
2 Cheap Stocks Top Managers Have Been Buying
-
The 10 Best Companies to Invest in Now